Alimera Sciences (ALIM) 6.31 $ALIM
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGM
SDV) (ASXVA.AX) declared on Monday that the US Food and Drug Administration (FDA) has set Prescription Drug User Fee Act (PDUFA) goal date of 26 September 2014 for ILUVIEN.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
Alimera Sciences Announces New PDUFA Date For ILUVIEN®
PR Newswire - Mon Apr 14, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN® has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's October 2013 letter and that a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 has been established.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 28, 7:21PM CDT
Cramer says the market needs both a China stimulus plan and positive U.S. employment numbers to sustain any gains.
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA
PR Newswire - Thu Mar 27, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera intends to provide that information when it becomes available.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA.
Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera", a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Alimera Sciences To Present At Citi 2014 Global Healthcare Conference
PR Newswire - Thu Feb 13, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera", a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY.
Alimera announces acceptance of ILUVIEN for NHS Scotland
M2 - Tue Feb 11, 7:22AM CST
US-based Alimera Sciences Inc (Nasdaq:ALIM), a biopharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, announced on Monday the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for restricted use within the National Health Service (NHS) Scotland.
Scottish Medicines Consortium Accepts ILUVIEN(R) For National Health Service Scotland
PR Newswire Europe - Mon Feb 10, 8:03AM CST
-- SMC advice follows positive NICE final guidance issued in November 2013
Scottish Medicines Consortium Accepts ILUVIEN® For National Health Service Scotland
PR Newswire - Mon Feb 10, 8:01AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within the National Health Service (NHS) Scotland.
8-K: ALIMERA SCIENCES INC
Edgar Online - Tue Feb 04, 12:47AM CST
ALIM-2014PIPE-Closing8-KDRAFT
Alimera Sciences Closes $37.5 Million Private Placement
PR Newswire - Mon Feb 03, 7:20AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it closed its previously announced private placement of common stock on January 31, 2014. Gross proceeds from the offering were approximately $37.5 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
Alimera Sciences signs purchase agreement with investors for USD37.5m private placement
M2 - Wed Jan 29, 5:07AM CST
Biopharmaceutical company Alimera Sciences Inc (Nasdaq:ALIM) announced on Tuesday that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately USD37.5m of its common stock in a private placement.
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGM
SDV) (ASXVA.AX) declared on Monday that the US Food and Drug Administration (FDA) has set Prescription Drug User Fee Act (PDUFA) goal date of 26 September 2014 for ILUVIEN. Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
Alimera Sciences Announces New PDUFA Date For ILUVIEN®
PR Newswire - Mon Apr 14, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN® has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's October 2013 letter and that a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 has been established.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 28, 7:21PM CDT
Cramer says the market needs both a China stimulus plan and positive U.S. employment numbers to sustain any gains.
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA
PR Newswire - Thu Mar 27, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera intends to provide that information when it becomes available.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA. Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Alimera Sciences To Present At Citi 2014 Global Healthcare Conference
PR Newswire - Thu Feb 13, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY. Alimera announces acceptance of ILUVIEN for NHS Scotland
M2 - Tue Feb 11, 7:22AM CST
US-based Alimera Sciences Inc (Nasdaq:ALIM), a biopharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, announced on Monday the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for restricted use within the National Health Service (NHS) Scotland.
Scottish Medicines Consortium Accepts ILUVIEN(R) For National Health Service Scotland
PR Newswire Europe - Mon Feb 10, 8:03AM CST
-- SMC advice follows positive NICE final guidance issued in November 2013
Scottish Medicines Consortium Accepts ILUVIEN® For National Health Service Scotland
PR Newswire - Mon Feb 10, 8:01AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within the National Health Service (NHS) Scotland.
8-K: ALIMERA SCIENCES INC
Edgar Online - Tue Feb 04, 12:47AM CST
ALIM-2014PIPE-Closing8-KDRAFT
Alimera Sciences Closes $37.5 Million Private Placement
PR Newswire - Mon Feb 03, 7:20AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it closed its previously announced private placement of common stock on January 31, 2014. Gross proceeds from the offering were approximately $37.5 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
Alimera Sciences signs purchase agreement with investors for USD37.5m private placement
M2 - Wed Jan 29, 5:07AM CST
Biopharmaceutical company Alimera Sciences Inc (Nasdaq:ALIM) announced on Tuesday that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately USD37.5m of its common stock in a private placement.
